-
Reply: Recognizing the new nomenclature requires a comprehensive analysis of the prevalence severity, and long-term outlook for SLD and subclassifications. Hepatology (IF 13.5) Pub Date : 2023-10-31 Brian P Lee,Jennifer L Dodge,Norah A Terrault
-
Reply: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis. Hepatology (IF 13.5) Pub Date : 2023-10-31 Wen-Juei Jeng,Rong-Nan Chien,Yun-Fan Liaw
-
Letter to the Editor: Cautious interpretation of the association between finite treatment and better prognosis in initially HBeAg-negative hepatitis B patients with cirrhosis. Hepatology (IF 13.5) Pub Date : 2023-10-31 Rui Deng,Ziyan Wang,Yuxin Liu,Jian Sun
-
Reply: "How to define the futile outcome in patients undergoing surgery for perihilar cholangiocarcinoma". Hepatology (IF 13.5) Pub Date : 2023-10-31 Francesca Ratti,Rebecca Marino,Bas Groot Koerkamp,Luca Aldrighetti
-
Letter to the Editor: Recognizing the new nomenclature requires a comprehensive analysis of the prevalence, severity, and long-term outlook for SLD and subclassifications. Hepatology (IF 13.5) Pub Date : 2023-10-31 Haoxuan Zou,Yan Xie
-
Mendelian Randomization in hepatology: A review of principles, opportunities, and challenges. Hepatology (IF 13.5) Pub Date : 2023-10-24 Yilin Song,Ting Ye,Lewis R Roberts,Nicholas B Larson,Stacey J Winham
Mendelian Randomization has become a popular tool to assess causal relationships using existing observational data. While randomized controlled trials are considered the gold standard for establishing causality between exposures and outcomes, it is not always feasible to conduct a trial. Mendelian Randomization is a causal inference method that uses observational data to infer causal relationships
-
FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1. Hepatology (IF 13.5) Pub Date : 2023-10-24 Changle Ke,Changchen Xiao,Jiamin Li,Xianpeng Wu,Yu Zhang,Yongjian Chen,Shuyuan Sheng,Zaiyang Fu,Lingjun Wang,Cheng Ni,Jing Zhao,Yanna Shi,Yan Wu,Zhiwei Zhong,Jinliang Nan,Wei Zhu,Jinghai Chen,Rongrong Wu,Xinyang Hu
BACKGROUND AND AIMS Nonalcoholic fatty liver disease (NAFLD), comprises a spectrum of liver disorders with the initial abnormal accumulation of lipids in hepatocytes called nonalcoholic fatty liver (NAFL), progressing to the more serious non-alcoholic steatohepatitis (NASH) in a subset of individuals. Our previous study revealed that global flavin-containing monooxygenase 2 (FMO2) knockout causes higher
-
Macrophage STING-YAP axis controls hepatic steatosis by promoting autophagic degradation of lipid droplets. Hepatology (IF 13.5) Pub Date : 2023-10-23 Tao Yang,Xiaoye Qu,Xiao Wang,Dongwei Xu,Mingwei Sheng,Yuanbang Lin,Michael Ke,Ci Song,Qiang Xia,Longfeng Jiang,Jun Li,Douglas G Farmer,Bibo Ke
BACKGROUND AIMS The hallmark of nonalcoholic fatty liver disease (NAFLD) or hepatic steatosis is characterized by lipid droplet (LD) accumulation in hepatocytes. Autophagy may have profound effects on lipid metabolism and innate immune response. However, how innate immune activation may regulate the autophagic degradation of intracellular LDs remains elusive. APPROACH RESULTS A mouse model of a high-fat
-
Adjuvant chemotherapy for resected biliary tract cancers: A fluorouracil-based scheme beats out a gemcitabine-based scheme for the win. Hepatology (IF 13.5) Pub Date : 2023-10-23 Ya-Fei Hu,Wen-Jie Ma,Yan-Wen Jin,Fu-Yu Li
-
AASLD practice guidance on risk stratification and management of portal hypertension and varices in cirrhosis. Hepatology (IF 13.5) Pub Date : 2023-10-23 David E Kaplan,Jaime Bosch,Cristina Ripoll,Maja Thiele,Brett E Fortune,Douglas A Simonetto,Guadalupe Garcia-Tsao
-
Wnt/β-catenin and NFκB signaling synergize to trigger growth-factor-free regeneration of adult primary human hepatocytes. Hepatology (IF 13.5) Pub Date : 2023-10-23 Nuria Oliva-Vilarnau,Christian M Beusch,Pierre Sabatier,Eirini Sakaraki,Amelie Tjaden,Lukas Graetz,Florian A Büttner,Debra Dorotea,My Nguyen,Filip Bergqvist,Yvonne Sundström,Susanne Müller,Roman A Zubarev,Gunnar Schulte,Claudia Tredup,Roberto Gramignoli,Uwe J F Tietge,Volker M Lauschke
BACKGROUND AIMS The liver has a remarkable capacity to regenerate, which is sustained by the ability of hepatocytes to act as facultative stem cells that, while normally quiescent, re-enter the cell cycle after injury. Growth factor signaling is indispensable in rodents, whereas Wnt/β-catenin is not required for effective tissue repair. However, the molecular networks that control human liver regeneration
-
A genetic basis of mitochondrial DNAJA3 in nonalcoholic steatohepatitis-related hepatocellular carcinoma. Hepatology (IF 13.5) Pub Date : 2023-10-23 Ching-Wen Chang,Yu-Syuan Chen,Chen-Hua Huang,Chao-Hsiung Lin,Wailap Victor Ng,Lichieh Julie Chu,Eric Trépo,Jessica Zucman-Rossi,Kevin Siao,Jacquelyn J Maher,Men Yee Chiew,Chih-Hung Chou,Hsien-Da Huang,Wan-Huai Teo,I-Shan Lee,Jeng-Fan Lo,Xin Wei Wang
BACKGROUND AIMS Nonalcoholic fatty liver disease (NAFLD) is the most common form of liver disease worldwide but only a subset of NAFLD individuals may progress to nonalcoholic steatohepatitis (NASH). While NASH is an important etiology of hepatocellular carcinoma (HCC), the underlying mechanisms responsible for conversion of NAFLD to NASH, and then to HCC are poorly understood. We aimed to identify
-
Association between hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis. Hepatology (IF 13.5) Pub Date : 2023-10-23 Robert G Gish,Robert J Wong,Gian Luca Di Tanna,Ankita Kaushik,Chong Kim,Nathaniel J Smith,Patrick T F Kennedy
BACKGROUND AIMS Studies have suggested that patients with chronic hepatitis B (CHB), either co-, or super infected, have more aggressive liver disease progression than those with the hepatitis delta virus (HDV). This systematic literature review and meta-analysis examined whether HDV RNA status is associated with increased risk of advanced liver disease events (ALDEs), in patients who are HBsAg and
-
Development of Fibro-PeN, a clinical prediction model for moderate to severe fibrosis in children with nonalcoholic fatty liver disease. Hepatology (IF 13.5) Pub Date : 2023-10-23 Andrew Wang,Amanda L Blackford,Cynthia Behling,Laura A Wilson,Kimberly P Newton,Stavra A Xanthakos,Mark H Fishbein,Miriam B Vos,Marialena Mouzaki,Jean P Molleston,Ajay K Jain,Paula Hertel,Kathryn Harlow Adams,Jeffrey B Schwimmer,
BACKGROUND AND AIMS Liver fibrosis is common in children with nonalcoholic fatty liver disease (NAFLD) and an important determinant of outcomes. High performing non-invasive models to assess fibrosis in children are needed. The objectives of this study were to evaluate the performance of existing pediatric and adult fibrosis prediction models and to develop a clinical prediction rule for identifying
-
Impact of radiological response and pattern of progression in patients with hepatocellular carcinoma treated by atezolizumab- bevacizumab. Hepatology (IF 13.5) Pub Date : 2023-10-23 Claudia Campani,Ariane Vallot,Haroun Ghannouchi,Manon Allaire,Manon Evain,Philippe Sultanik,Sabrina Sidali,Lorraine Blaise,Dominique Thabut,Pierre Nahon,Olivier Seror,Nathalie Ganne-Carrié,Jean-Charles Nault,Mathilde Wagner,Olivier Sutter
BACKGROUND AIMS We aim to assess the role of radiological response to atezolizumab-bevacizumab (AtezoBev) in patients with hepatocellular carcinoma (HCC) to predict overall survival (OS). APPROACH RESULTS We retrospectively included HCC patients treated by AtezoBev in two tertiary centers. A retrospective blinded analysis was performed by two radiologists to assess RECIST1.1 and mRECIST criteria at
-
Validation of AGA clinical care pathway and AASLD practice guidance for nonalcoholic fatty liver disease in a prospective cohort of patients with type 2 diabetes. Hepatology (IF 13.5) Pub Date : 2023-10-20 Veeral Ajmera,Kaleb Tesfai,Erick Sandoval,Scarlett Lopez,Vanessa Cervantes,Egbert Madamba,Ricki Bettencourt,Pinelopi Manousou,Lisa Richards,Rohit Loomba
BACKGROUND AND AIMS Recently, the American Gastroenterological Association (AGA) and American Association for the Study of Liver Diseases (AASLD) developed clinical pathways to evaluate populations at high-risk for nonalcoholic fatty liver disease (NAFLD). We assessed the diagnostic performance of the new guidance in a well-phenotyped cohort of patients with Type 2 diabetes mellitus (T2DM). APPROACH
-
Letter to the Editor: Contrasting effect of iron supplementation iron in protoporpyria. Hepatology (IF 13.5) Pub Date : 2023-10-20 Jasmin Barman-Aksözen,Anna-Elisabeth Minder,Detlef Schuppan,Ulrich Stölzel
-
Letter to the Editor: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding? Hepatology (IF 13.5) Pub Date : 2023-10-20 Edo J Dongelmans,Milan J Sonneveld,Harry L A Janssen
-
New insights into the molecular basis of alcohol abstinence and relapse in alcohol-associated liver disease. Hepatology (IF 13.5) Pub Date : 2023-10-20 Luis Antonio Diaz,Gerald Scott Winder,Lorenzo Leggio,Jasmohan S Bajaj,Ramon Bataller,Juan Pablo Arab
Alcohol use disorder (AUD) remains a significant public health concern, affecting around 5% of adults worldwide. Novel pathways of damage have been described during the last years, providing insight into the mechanism of injury due to alcohol misuse beyond the direct effect of ethanol byproducts on the liver parenchyma and neurobehavioral mechanisms. Thus, the gut-liver-brain axis and immune system
-
Reply: Benefits of stopping therapy in cirrhotic hepatitis B patients, true effect or residual confounding? Hepatology (IF 13.5) Pub Date : 2023-10-20 Yun-Fan Liaw,Wen-Juei Jeng,Rong-Nan Chien
-
The Liver Meeting: Boston, Massachusetts Nov 10-14, 2023. Hepatology (IF 13.5) Pub Date : 2023-10-12
-
ZNT1 and Zn2+ control TLR4 and PD-L1 endocytosis in macrophage to improve chemotherapy efficacy against liver tumor. Hepatology (IF 13.5) Pub Date : 2023-10-09 Dan Yang,Taikun Tian,Xiaojing Li,Baokai Zhang,Linlin Qi,Fan Zhang,Mingshun Han,Shuang Wang,Jun Xiao,Yingying Gou,Raorao Zhang,Qiaojie Liu,Sheng Su,Jiahui Liu,Xiaowu Huang,Qiang Gao,Lijian Hui,Huiru Tang,Hongyan Wang,Bin Wei
BACKGROUND AIMS Hepatocellular carcinoma (HCC) is closely associated with inflammation and immune modulation, and combined chemotherapy with other strategies is under extensive investigation to achieve better efficacy. HCC is accompanied by zinc deficiency. This study aims to understand how zinc could affect macrophage function and its application for HCC therapy. APPROACH RESULTS Zn2+ and the zinc
-
Reply: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon. Hepatology (IF 13.5) Pub Date : 2023-10-09 Randa Elsheikh,Abdelrahman M Makram,Nguyen Tien Huy
-
Unlocking the immune microenvironment of non-alcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology (IF 13.5) Pub Date : 2023-10-09 Stephanie Ma,Valerie Chew
-
Letter to the Editor: Outbreak of indeterminate acute hepatitis in children, not a new disease but an epidemiological phenomenon. Hepatology (IF 13.5) Pub Date : 2023-10-09 Barath Jagadisan,Anil Dhawan
-
Risk of liver-related events in metabolic dysfunction-associated steatohepatitis (MASH) patients with fibrosis: A comparative analysis of various risk stratification criteria. Hepatology (IF 13.5) Pub Date : 2023-10-02 Grazia Pennisi,Marco Enea,Manuel Romero-Gomez,Elisabetta Bugianesi,Vincent Wai-Sun Wong,Anna Ludovica Fracanzani,Victor de Ledinghen,Jacob George,Annalisa Berzigotti,Mauro Viganò,Giada Sebastiani,Roberto Cannella,Adèle Delamarre,Gabriele Di Maria,Naomi F Lange,Adele Tulone,Vito Di Marco,Calogero Cammà,Salvatore Petta
BACKGROUND International regulatory agencies recommend testing drug therapy for patients with noncirrhotic high-risk metabolic dysfunction-associated steatohepatitis (MASH) because they are at risk of liver-related events(LRE). We aimed to compare the risk of LRE in MASLD patients stratified for F2-F4 fibrosis and MASH. METHODS 1938 consecutive patients with biopsy-proven MASLD were enrolled. High-risk
-
Genomic approaches to explore susceptibility and pathogenesis of alcohol use disorder and alcohol-associated liver disease. Hepatology (IF 13.5) Pub Date : 2023-10-02 Trina M Norden-Krichmar,Daniel Rotroff,Tae-Hwi Schwantes-An,Ramon Bataller,David Goldman,Laura E Nagy,Suthat Liangpunsakul
Excessive alcohol use is a major risk factor for the development of an alcohol use disorder (AUD) and contributes to a wide variety of other medical illnesses, including alcohol-associated liver disease (ALD). Both AUD and ALD are complex and causally inter-related diseases, and multiple factors other than alcohol consumption are implicated in the disease pathogenesis. While the underlying pathophysiology
-
Pre-emptive TIPS in high-risk acute variceal bleeding. An updated and revised individual patient data meta-analysis. Hepatology (IF 13.5) Pub Date : 2023-10-02 Oana Nicoară-Farcău,Guohong Han,Marika Rudler,Debora Angrisani,Alberto Monescillo,Ferran Torres,Georgina Casanovas,Jaime Bosch,Yong Lv,Philip D J Dunne,Peter C Hayes,Dominique Thabut,Daiming Fan,Virginia Hernández-Gea,Juan Carlos García-Pagán,
BACKGROUND AIMS A previous individual patient data meta-analysis (IPD-MA) showed that compared with drugs+endoscopy, placement of transjugular portosystemic shunt within 72 hrs of admission (preemptive TIPS: p-TIPS) increases the survival of high-risk patients (Child-Pugh B+active bleeding and Child-Pugh C<14points) with cirrhosis and acute variceal bleeding (AVB). However, previous IPD-MA was not
-
-
The clinical and financial burden of nonhepatocellular carcinoma focal lesions detected during surveillance of patients with cirrhosis. Hepatology (IF 13.5) Pub Date : 2023-09-29 Pierre Nahon,Richard Layese,Nathalie Ganne-Carrié,Cécile Moins,Gisèle N'Kontchou,Cendrine Chaffaut,Maxime Ronot,Etienne Audureau,Isabelle Durand-Zaleski,Pierre-André Natella,
BACKGROUND AND AIMS Hepatocellular carcinoma (HCC) surveillance is challenged by the detection of hepatic focal lesions (HFLs) of other types. This study aimed to describe the incidence, characteristics, outcomes and costs of non-HCC HFL detected during surveillance. APPROACH AND RESULTS We retrospectively analyzed non-standardized workup performed in French patients included in HCC surveillance programs
-
-
Letter to the Editor: Effect of tenofovir-based HIV pre-exposure prophylaxis against HBV infection in men who have sex with men. Hepatology (IF 13.5) Pub Date : 2023-09-22 Chien-Tzu Hung,Shih-Jer Hsu,Chun-Jen Liu
-
Canonical Wnt signaling promotes HSC glycolysis and liver fibrosis through an LDH-A/HIF-1α transcriptional complex. Hepatology (IF 13.5) Pub Date : 2023-09-21 Feixia Wang,Li Chen,Desong Kong,Xiaojin Zhang,Siwei Xia,Baoyu Liang,Yang Li,Ya Zhou,Zili Zhang,Jiangjuan Shao,Shizhong Zheng,Feng Zhang
BACKGROUND AND AIMS Aerobic glycolysis reprogramming occurs during HSC activation, but how it is initiated and sustained remains unknown. We investigated the mechanisms by which canonical Wnt signaling regulated HSC glycolysis and the therapeutic implication for liver fibrosis. APPROACH AND RESULTS Glycolysis was examined in HSC-LX2 cells upon manipulation of Wnt/β-catenin signaling. Nuclear translocation
-
Spatial proteomics of immune microenvironment in nonalcoholic steatohepatitis-associated hepatocellular carcinoma. Hepatology (IF 13.5) Pub Date : 2023-09-21 Meiyi Li,Lina Wang,Liang Cong,Chi Chun Wong,Xiang Zhang,Huarong Chen,Tao Zeng,Bin Li,Xian Jia,Jihui Huo,Yuhua Huang,Xiaoxue Ren,Sui Peng,Guo Fu,Lixia Xu,Joseph Jy Sung,Ming Kuang,Xiaoxing Li,Jun Yu
BACKGROUND AND AIMS NASH-HCC is inherently resistant to immune checkpoint blockade, but its tumor immune microenvironment is largely unknown. APPROACH AND RESULTS We applied the imaging mass cytometry to construct a spatially resolved single-cell atlas from the formalin-fixed and paraffin-embedded tissue sections from patients with NASH-HCC, virus-HCC (HBV-HCC and HCV-HCC), and healthy donors. Based
-
A randomized, double-blind, placebo-controlled trial of Aldafermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis. Hepatology (IF 13.5) Pub Date : 2023-09-21 Mary E Rinella,Hsiao D Lieu,Kris V Kowdley,Zachary D Goodman,Naim Alkhouri,Eric Lawitz,Vlad Ratziu,Manal F Abdelmalek,Vincent Wai-Sun Wong,Ziad H Younes,Aasim M Sheikh,Donald Brannan,Bradley Freilich,Fernando Membreno,Marie Sinclair,Liza Melchor-Khan,Arun J Sanyal,Lei Ling,Stephen A Harrison
BACKGROUND AND AIMS Aldafermin, an engineered analog of the human hormone FGF19, improves liver histology in patients with non-cirrhotic nonalcoholic steatohepatitis (NASH), however, its efficacy and safety in compensated cirrhosis is unknown. No drug has yet to demonstrate benefit in the compensated NASH population. APPROACH AND RESULTS In this multicenter, double-blind, placebo-controlled, phase
-
Physiologic changes in the hepatopulmonary syndrome before and after liver transplant: A longitudinal and predictor analysis. Hepatology (IF 13.5) Pub Date : 2023-09-21 Xun Zhao,Sreelakshmi Kotha,Dhruv Nayyar,Xiayi Ma,Leslie Lilly,Hélène Castel,Samir Gupta
BACKGROUND AND AIMS Hepatopulmonary syndrome (HPS) is a common complication of liver disease defined by abnormal oxygenation and intrapulmonary vascular dilatation, treated with liver transplantation. Little is known about changes in HPS physiological parameters over time. We sought to describe baseline clinical and physiological characteristics in HPS and their relationships, temporal changes in physiological
-
National prevalence estimates for steatotic liver disease and Sub-Classifications using consensus nomenclature. Hepatology (IF 13.5) Pub Date : 2023-09-20 Brian P Lee,Jennifer L Dodge,Norah A Terrault
BACKGROUND AIMS The multisociety consensus nomenclature has renamed non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD) with various sub-classifications. There is paucity of data regarding how the new nomenclature modifies our understanding of disease prevalence and patient phenotypes. APPROACH RESULTS Using the National Health and Nutrition Examination Survey from 1/2017-3/2020
-
Computational drug prediction in hepatoblastoma by integrating pan-cancer transcriptomics with pharmacological response. Hepatology (IF 13.5) Pub Date : 2023-09-20 Mario Failli,Salih Demir,Álvaro Del Río-Álvarez,Juan Carrillo-Reixach,Laura Royo,Montserrat Domingo-Sàbat,Margaret Childs,Rudolf Maibach,Rita Alaggio,Piotr Czauderna,Bruce Morland,Sophie Branchereau,Stefano Cairo,Roland Kappler,Carolina Armengol,Diego di Bernardo
Hepatoblastoma (HB) is the main paediatric liver cancer, but it is a very rare disease. Despite significant improvements in the treatment of children diagnosed with HB, limited treatment options exist for patients with advanced tumours. Besides, survivors generally have long-term adverse effects derived from treatment such as ototoxicity, cardiotoxicity, delayed growth, and secondary tumours. Accordingly
-
Telomere length and risk of cirrhosis, hepatocellular carcinoma, and cholangiocarcinoma in 63,272 individuals from the general population. Hepatology (IF 13.5) Pub Date : 2023-09-19 Helene Gellert-Kristensen,Stig E Bojesen,Anne Tybjærg-Hansen,Stefan Stender
BACKGROUND AIMS Inherited short telomeres are associated with risk of liver disease, whereas longer telomeres predispose to cancer. The association between telomere length and risk of hepatocellular carcinoma and cholangiocarcinoma remains unknown. APPROACH RESULTS We measured leukocyte telomere length using multiplex PCR in 63,272 individuals from the Danish general population. Telomere length and
-
Letter to Editor: NAFLD improves risk prediction of type 2 diabetes: With effect modification by sex and menopausal status. Hepatology (IF 13.5) Pub Date : 2023-09-19 Mubashra Khalid,Zoraiz Munir Khan,Ahmad Sheraz Kahloon
-
Obesity management for the hepatologist - what to do, how to do it and why. Hepatology (IF 13.5) Pub Date : 2023-09-19 Kymberly D Watt,Sonali Paul,Mohammad Qasim Khan,Mohammad Siddiqui,Jenny Lam,Tayyab S Diwan,Michael Camilleri
Obesity is highly prevalent in hepatology clinics and has significant impact in chronic liver disease and patient management. Hepatologists and gastroenterologist need to be actively engaged in the management of obesity. This review provides a detailed approach to this challenging comorbidity.
-
Bile acid-induced IRF3 phosphorylation mediates cell death, inflammatory responses and fibrosis in cholestasis-induced liver and kidney injury via regulation of ZBP1. Hepatology (IF 13.5) Pub Date : 2023-09-19 Yuan Zhuang,Martí Ortega-Ribera,Prashanth Thevkar Nagesh,Radhika Joshi,Huihui Huang,Yanbo Wang,Adam Zivny,Jeeval Mehta,Samir M Parikh,Gyongyi Szabo
Cell death and inflammation play critical roles in chronic tissue damage caused by cholestatic liver injury leading to fibrosis and cirrhosis. Liver cirrhosis is often associated with kidney damage that is a severe complication with poor prognosis. Interferon regulatory factor 3 (IRF3) is known to regulate apoptosis and inflammation, but its role in cholestasis remains obscure. In this study, we discovered
-
Hypoxia-driven tumor stromal remodeling and immunosuppressive microenvironment in scirrhous hepatocellular carcinoma. Hepatology (IF 13.5) Pub Date : 2023-09-19 Shuling Chen,Changyi Liao,Huanjing Hu,Junbin Liao,Zebin Chen,Shuang Li,Xuezhen Zeng,Bo Peng,Shunli Shen,Dongming Li,Shaoqiang Li,Jiaming Lai,Sui Peng,Yubin Xie,Ming Kuang
BACKGROUND AND AIMS Scirrhous hepatocellular carcinoma (SHCC) is one of the unique subtypes of hepatocellular carcinoma (HCC), characterized by abundant fibrous stroma in tumor microenvironment. However, it remains unclear about the molecular traits of SHCC, which is essential to develop specialized therapeutic approaches for SHCC. APPROACH RESULTS We presented an integrative analysis containing single-cell
-
Higher need for polycystic liver disease therapy in female patients: sex-specific association between liver volume and need for therapy. Hepatology (IF 13.5) Pub Date : 2023-09-19 Thijs R M Barten,Femke Atsma,Adriaan J van der Meer,Ron Gansevoort,Frederik Nevens,Joost P H Drenth,Tom J G Gevers
BACKGROUND AIM Prognostic tools or biomarkers are urgently needed in polycystic liver disease (PLD) to monitor disease progression and evaluate treatment outcomes. Total liver volume (TLV) is currently used to assess cross-sectional disease severity and female patients typically have larger livers than males. Therefore, this study explores the sex-specific association between TLV and volume reducing
-
Spatial proximity of Tumor-Immune interactions predicts patient outcome in hepatocellular carcinoma. Hepatology (IF 13.5) Pub Date : 2023-09-19 Evan Maestri,Noemi Kedei,Subreen Khatib,Marshonna Forgues,Kris Ylaya,Stephen M Hewitt,Limin Wang,Jittiporn Chaisaingmongkol,Mathuros Ruchirawat,Lichun Ma,Xin Wei Wang
BACKGROUND AND AIMS The fitness and viability of a tumor ecosystem are influenced by the spatial organization of its cells. We aimed to study the structure, architecture, and cell-cell dynamics of the heterogenous liver cancer tumor microenvironment using spatially resolved multiplexed imaging. APPROACH AND RESULTS We performed co-detection by indexing (CODEX) multiplexed immunofluorescence imaging
-
Scirrhous HCC: Another 'omic thread in the HCC tapestry. Hepatology (IF 13.5) Pub Date : 2023-09-19 Joseph W Franses,Dan G Duda
-
The clinical imperative of a complete biochemical response to immunosuppression in autoimmune hepatitis: Close is not good enough! Hepatology (IF 13.5) Pub Date : 2023-09-18 George Cholankeril,John M Vierling
-
CEUS for HCC: Finally out from the waiting list? Hepatology (IF 13.5) Pub Date : 2023-09-18 Richard G Barr,Luigi Bolondi
-
-
The rapidly evolving landscape of HCC: Selecting the optimal systemic therapy. Hepatology (IF 13.5) Pub Date : 2023-09-11 Valentina Zanuso,Lorenza Rimassa,Chiara Braconi
Over the past years, there has been a remarkable advance in the systemic treatment options for advanced HCC. The overall survival has gradually increased over time, with larger benefits for patients with sensitive tumors and preserved liver function, the latter being an essential condition for the delivery of sequential lines of treatment and optimization of clinical outcomes. With the approval of
-
Single-cell immune profiling of mouse liver aging reveals Cxcl2+ macrophages recruit neutrophils to aggravate liver injury. Hepatology (IF 13.5) Pub Date : 2023-09-11 Yasong Liu,Jiaqi Xiao,Jianye Cai,Rong Li,Xin Sui,Jiebin Zhang,Tongyu Lu,Haitian Chen,Guihua Chen,Haibo Li,Chenhao Jiang,Xuegang Zhao,Cuicui Xiao,Yunguo Lei,Jia Yao,Guo Lv,Jinliang Liang,Yingcai Zhang,Jian-Rong Yang,Jun Zheng,Yang Yang
BACKGROUND AND AIMS Immune cells play a crucial role in liver aging. However, the impact of dynamic changes in the local immune microenvironment on age-related liver injury remains poorly understood. We aimed to characterize intrahepatic immune cells at different ages to investigate key mechanisms associated with liver aging. APPROACH AND RESULTS We carried out single-cell RNA sequencing (scRNA-seq)
-
Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: first report of the IAIHG retrospective registry. Hepatology (IF 13.5) Pub Date : 2023-09-04 Charlotte D Slooter,Floris F van den Brand,Ana Lleo,Francesca Colapietro,Marco Lenzi,Paolo Muratori,Nanda Kerkar,George N Dalekos,Kalliopi Zachou,M Isabel Lucena,Mercedes Robles-Díaz,Daniel E Di Zeo-Sánchez,Raúl J Andrade,Aldo J Montano-Loza,Ellina Lytvyak,Birgit I Lissenberg-Witte,Patrick Maisonneuve,Gerd Bouma,Guilherme Macedo,Rodrigo Liberal,Ynto S de Boer,,,
BACKGROUND AND AIM The International Autoimmune hepatitis (AIH) Group retrospective registry (IAIHG-RR) is a web-based platform with subjects enrolled with a clinical diagnosis of AIH. As prognostic factor studies with enough power are scarce, this study aimed to ascertain data quality and identify prognostic factors in the IAIHG-RR cohort. METHODS This retrospective, observational, multicenter study
-
LIM domain only 7 negatively controls non-alcoholic steatohepatitis in the setting of hyperlipidaemia. Hepatology (IF 13.5) Pub Date : 2023-09-01 Tiangen Wu,Xi Chen,Kequan Xu,Caixia Dai,Xiaomian Li,Yang-Wen-Qing Zhang,Jinghua Li,Meng Gao,Yingyi Liu,Fusheng Liu,Xutao Zhang,Bicheng Wang,Peng Xia,Zhen Li,Weijie Ma,Yufeng Yuan
BACKGROUND AND AIMS Hyperlipidemia has been extensively recognized as a high-risk factor for non-alcoholic steatohepatitis (NASH); however, clinical susceptibility to NASH is highly heterogeneous. The key controller(s) of NASH susceptibility in patients with hyperlipidemia have not yet been elucidated. Here, we aimed to reveal the key regulators of NASH in patients with hyperlipidemia and to explore
-
Pegylated interferon-α for chronic hepatitis B … not ready to be shelved yet! New insights on its role using single-cell transcriptomics. Hepatology (IF 13.5) Pub Date : 2023-09-01 Upkar S Gill,Dimitra Peppa
-
The chronicles of hepatocellular carcinoma classification: Subtyping, modeling and treatment. Hepatology (IF 13.5) Pub Date : 2023-08-30 Shu Shimada,Shinji Tanaka
-
Letter to the Editor: NAFLD, MAFLD or MASLD? Cut the Gordian knot with "Ludwig disease". Hepatology (IF 13.5) Pub Date : 2023-08-30 Enzo Emanuele,Piercarlo Minoretti
-
Reply: NAFLD, MAFLD or MASLD? cut the gordian knot with "Ludwig disease". Hepatology (IF 13.5) Pub Date : 2023-08-30 Philip Newsome,Mary E Rinella,Jeffrey V Lazarus,Norah Terrault
-
HDV RNA Assays: Performance characteristics, clinical utility and challenges. Hepatology (IF 13.5) Pub Date : 2023-08-28 Heiner Wedemeyer,Mitchell Leus,Thomas R Battersby,Jeffrey Glenn,Emmanuel Gordien,Saleem Kamili,Hema Kapoor,Harald H Kessler,Oliver Lenz,Marc Lütgehetmann,Tonya Mixson-Hayden,Christian O Simon,Michael Thomson,Gabriel Westman,Veronica Miller,Norah Terrault,Pietro Lampertico,
Co-infection with hepatitis B virus (HBV) and hepatitis D virus (HDV) results in hepatitis D, the most severe form of chronic viral hepatitis, frequently leading to liver decompensation and hepatocellular carcinoma. Pegylated interferon alpha, the only treatment option for chronic hepatitis D for many years, has limited efficacy. New treatments are in advanced clinical development, with one recent
-
Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression. Hepatology (IF 13.5) Pub Date : 2023-08-25 Ines Volkert,Malin Fromme,Carolin Schneider,Lena Candels,Cecilia Lindhauer,Huan Su,Katrine Thorhauge,Monica Pons,Mohamed Ramadan Mohamed,Kai Markus Schneider,Pavel Strnad,Christian Trautwein
BACKGROUND AND AIMS Genetic risk factors are major determinants of chronic liver disease (CDL) progression. Patatin-like phospholipase domain-containing protein 3 (PNPLA3) I148M polymorphism and alpha-1 antitrypsin E342K variant, termed PiZ, are major modifiers of metabolic CLD. Both variants are known to affect metabolic CLD via increased endoplasmic reticulum stress, but their combined effect on
-
Medications for alcohol use disorder promote abstinence in alcohol-related cirrhosis: results from a systematic review and meta-analysis. Hepatology (IF 13.5) Pub Date : 2023-08-25 Jordi Gratacós-Ginès,Pol Bruguera,Martina Pérez-Guasch,Ana López-Lazcano,Roger Borràs,Helena Hernández-Évole,Maria T Pons-Cabrera,Anna Lligoña,Ramón Bataller,Pere Ginès,Hugo López-Pelayo,Elisa Pose
BACKGROUND the role of medications for alcohol use disorder (MAUD) in patients with cirrhosis is not well established. Evidence on the efficacy and safety of these drugs in these patients is scarce. Approach & results: we performed a systematic review and meta-analysis according to PRISMA guidelines on the efficacy of MAUD in patients with cirrhosis. Search was conducted in PubMed, Embase and Scopus